Literature DB >> 3034215

Effect of recombinant human interferon gamma against human cytomegalovirus.

N Yamamoto, K Shimokata, K Maeno, Y Nishiyama.   

Abstract

Escherichia coli-derived human interferon-gamma (rIFN-gamma) inhibited the replication of human cytomegalovirus (HCMV) synergistically when combined with IFN-alpha. The induction of HCMV DNA polymerase was inhibited in rIFN-gamma-treated cells. It is suggested that the induction of 2-5 A synthetase does not play an important role in the anti-HCMV actions of IFNs.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3034215     DOI： 10.1007/BF01310726

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  9 in total

1.  Factors affecting the interferon sensitivity of human cytomegalovirus.

Authors:  A R Holmes; L Rasmussen; T C Merigan
Journal:  Intervirology       Date:  1978       Impact factor: 1.763

2.  Interstitial pneumonia and cytomegalovirus infection as complications of human marrow transplantation.

Authors:  P Neiman; P B Wasserman; B B Wentworth; G F Kao; K G Lerner; R Storb; C D Buckner; R A Clift; A Fefer; L Fass; H Glucksberg; E D Thomas
Journal:  Transplantation       Date:  1973-05       Impact factor: 4.939

3.  Synthesis of human cytomegalovirus-specified RNA and protein in interferon-treated cells at early times after infection.

Authors:  M F Stinski; D R Thomsen; J E Rodriguez
Journal:  J Gen Virol       Date:  1982-06       Impact factor: 3.891

4.  Resistance of vaccinia virus to interferon is related to an interference phenomenon between the virus and the interferon system.

Authors:  E Paez; M Esteban
Journal:  Virology       Date:  1984-04-15       Impact factor: 3.616

5.  Effects of acyclovir combined with other antiviral agents on human cytomegalovirus.

Authors:  S A Spector; M Tyndall; E Kelley
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

6.  Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation.

Authors:  J D Meyers; R W McGuffin; P E Neiman; J W Singer; E D Thomas
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

7.  Characterization of human cytomegalovirus-induced DNA polymerase and the associated 3'-to-5', exonuclease.

Authors:  Y Nishiyama; K Maeno; S Yoshida
Journal:  Virology       Date:  1983-01-30       Impact factor: 3.616

8.  Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon.

Authors:  J C Wade; R W McGuffin; S C Springmeyer; B Newton; J W Singer; J D Meyers
Journal:  J Infect Dis       Date:  1983-09       Impact factor: 5.226

9.  Enhanced capacity of DNA repair in human cytomegalovirus-infected cells.

Authors:  Y Nishiyama; F Rapp
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103
  9 in total
  3 in total

1.  Engagement of the cellular receptor for glycoprotein B of human cytomegalovirus activates the interferon-responsive pathway.

Authors:  K A Boyle; R L Pietropaolo; T Compton
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung.

Authors:  H A Jaffe; R Buhl; A Mastrangeli; K J Holroyd; C Saltini; D Czerski; H S Jaffe; S Kramer; S Sherwin; R G Crystal
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma.

Authors:  Bruno Sainz; Heather L LaMarca; Robert F Garry; Cindy A Morris
Journal:  Virol J       Date:  2005-02-23       Impact factor: 4.099
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.